Immune checkpoints and immunotherapy for colorectal cancer

Preet Paul Singh, Piyush K. Sharma, Gayathri Krishnan, Albert Lockhart

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

Original languageEnglish (US)
Pages (from-to)289-297
Number of pages9
JournalGastroenterology Report
Volume3
Issue number4
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Immunotherapy
Colorectal Neoplasms
Drug Therapy
DNA Mismatch Repair
Biological Products
Cause of Death
Clinical Trials
Survival
Neoplasms
Therapeutics

Keywords

  • Checkpoint inhibition/blockade
  • Colorectal cancer
  • Cytotoxic Tlymphocyte- associated antigen 4 (CTLA-4)
  • Immunotherapy
  • Pembrolizumab
  • Programmed death 1 (PD-1)
  • Vaccine

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Immune checkpoints and immunotherapy for colorectal cancer. / Singh, Preet Paul; Sharma, Piyush K.; Krishnan, Gayathri; Lockhart, Albert.

In: Gastroenterology Report, Vol. 3, No. 4, 01.11.2015, p. 289-297.

Research output: Contribution to journalReview article

Singh, Preet Paul ; Sharma, Piyush K. ; Krishnan, Gayathri ; Lockhart, Albert. / Immune checkpoints and immunotherapy for colorectal cancer. In: Gastroenterology Report. 2015 ; Vol. 3, No. 4. pp. 289-297.
@article{1467dddb0fcf4049bc628fc1119eaf02,
title = "Immune checkpoints and immunotherapy for colorectal cancer",
abstract = "Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.",
keywords = "Checkpoint inhibition/blockade, Colorectal cancer, Cytotoxic Tlymphocyte- associated antigen 4 (CTLA-4), Immunotherapy, Pembrolizumab, Programmed death 1 (PD-1), Vaccine",
author = "Singh, {Preet Paul} and Sharma, {Piyush K.} and Gayathri Krishnan and Albert Lockhart",
year = "2015",
month = "11",
day = "1",
doi = "10.1093/gastro/gov053",
language = "English (US)",
volume = "3",
pages = "289--297",
journal = "Gastroenterology Report",
issn = "2052-0034",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Immune checkpoints and immunotherapy for colorectal cancer

AU - Singh, Preet Paul

AU - Sharma, Piyush K.

AU - Krishnan, Gayathri

AU - Lockhart, Albert

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

AB - Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

KW - Checkpoint inhibition/blockade

KW - Colorectal cancer

KW - Cytotoxic Tlymphocyte- associated antigen 4 (CTLA-4)

KW - Immunotherapy

KW - Pembrolizumab

KW - Programmed death 1 (PD-1)

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85045371624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045371624&partnerID=8YFLogxK

U2 - 10.1093/gastro/gov053

DO - 10.1093/gastro/gov053

M3 - Review article

AN - SCOPUS:85045371624

VL - 3

SP - 289

EP - 297

JO - Gastroenterology Report

JF - Gastroenterology Report

SN - 2052-0034

IS - 4

ER -